Class IIa Medical Device Requirements (MDR)

A device that lands in MDR Class IIa sits in the middle tier of the EU Medical Device Regulation’s four-class risk ladder (Regulation (EU) 2017/745, applicable since 26 May 2021). This guide is not about how the classification rules assign that tier — that is a separate exercise under MDR Annex VIII. It is about what changes for a manufacturer once a device is confirmed as Class IIa: which conformity assessment route is available, how much of your technical documentation a notified body actually reviews, how deep the clinical evaluation requirement runs, and how often you owe a periodic safety update report. Those four obligations look similar in name across MDR’s classes but differ sharply in scope, and Class IIa’s specific mix is easy to get wrong by assuming it works like Class I (self-declared) or Class III (fully reviewed device-by-device).

Where Class IIa sits on the risk ladder

MDR’s four device classes — I, IIa, IIb, and III — are assigned under 22 classification rules in Annex VIII, grouped by how invasive the device is, how long it contacts the body, and whether it is active (powered) or administers/removes a substance. Class IIa covers devices carrying a moderate risk profile: commonly cited examples include hearing aids, diagnostic ultrasound equipment, most non-invasive devices intended to channel or store blood or body fluids for eventual infusion or administration, and many short-term invasive or active diagnostic devices. It sits above Class I (low risk, generally self-declared) and below Class IIb and Class III (higher risk, more intensive review). If you are still working out whether your device is Class IIa in the first place, that determination runs through Annex VIII’s classification rules rather than anything in this guide — what follows assumes classification is already settled.

Conformity assessment: the routes available to a Class IIa manufacturer

Article 52 of MDR sets out which conformity assessment procedure applies to which class. A Class IIa manufacturer (other than for custom-made or investigational devices, which follow separate rules) has, in practice, two routes:

Annex IX, Chapters I and III — the notified body assesses the manufacturer’s quality management system (design, manufacture, and final inspection) and separately evaluates the technical documentation. This is the route most Class IIa manufacturers use, largely because it does not require the device-by-device design-dossier examination that Annex IX Chapter II imposes on Class III devices.
Annex XI, Part A (production quality assurance), combined with a technical documentation assessment — a less commonly chosen alternative that shifts the quality-system assessment’s emphasis toward production rather than full design-and-manufacture QMS coverage.

Either way, the notified body issues an EU technical documentation assessment (where applicable) and a QMS certificate, and the manufacturer then draws up the EU declaration of conformity and applies the CE mark. There is no route by which a Class IIa device is self-certified by the manufacturer alone — that option effectively ends at Class I (with narrow exceptions for sterile, measuring, and reusable-surgical-instrument Class I devices, which need notified body involvement only on that specific aspect).

How much technical documentation actually gets reviewed

This is the detail that most often trips up manufacturers moving up from Class I or down in expectations from Class III. Under the Annex IX route, the notified body does not examine every individual device variant in a Class IIa product line. Technical documentation is assessed on a representative basis — broadly, at least one representative device per generic device group, rather than a full design-dossier review of each catalogue variant. That is a materially lighter review burden than Class III (and implantable Class IIb devices), where the notified body’s design-examination obligations reach much further into each specific device. It does not mean a Class IIa device escapes scrutiny; it means the depth of scrutiny is calibrated to the device group rather than to every SKU a manufacturer sells under it.

Notified body involvement: what it actually covers

For a Class IIa device, notified body involvement is not optional and it is not a one-time event. Beyond the initial conformity assessment described above, the QMS certificate is subject to ongoing surveillance audits (routine, scheduled) plus unannounced audits the notified body is required to build into its oversight, particularly around new manufacturing sites, changed processes, or post-market safety signals. See CASRAI’s guide to notified body designation and audits for how that oversight relationship works in practice, and confirm any notified body you are evaluating actually holds Class IIa within its published scope in NANDO, the European Commission’s public database of designated conformity assessment bodies — scope is device-category specific, not a blanket credential.

Clinical evaluation depth for Class IIa

Article 61 governs clinical evaluation for every MDR device class, but the depth of what satisfies it differs sharply by class. Class III and implantable devices generally must be supported by a dedicated pre-market clinical investigation under Article 61(4), with only narrow, specifically defined exemptions. Class IIa devices are not held to that bar: under Article 61(10), clinical evaluation can be based on sufficient clinical data drawn from literature, equivalent-device data, and the manufacturer’s own post-market clinical follow-up (PMCF), without a dedicated clinical investigation being mandatory — provided the requirements of Annex XIV Part A are actually met and any claimed equivalence satisfies Article 61(5)’s technical, biological, and clinical criteria. In practice, this means a well-documented literature-and-equivalence clinical evaluation report is usually sufficient for a Class IIa device where a genuinely equivalent predicate exists; where it does not, the manufacturer still needs to generate the missing clinical evidence some other way, just not necessarily through a formal clinical investigation.

Post-market surveillance and PSUR frequency

MDR’s post-market surveillance obligations scale with class, and this is where Class IIa’s specific position is easiest to misstate. Article 83 sets the general obligation to establish and maintain a PMS system, proportionate to risk class, for every device. Article 84 requires a PMS plan (part of the technical documentation), and Article 86 requires a periodic safety update report (PSUR) for Class IIa, IIb, and III devices — Class I devices instead file the lighter PMS report under Article 85, updated only when necessary.

For Class IIa specifically, the PSUR must be updated when necessary and at least every two years, and it needs only to be made available to the notified body on request — it is not proactively submitted. That is a meaningfully lighter cadence than Class IIb and Class III, where the PSUR must be updated at least annually and is actively submitted to the notified body (with Eudamed availability once that module is in force). See CASRAI’s guides to the post-market surveillance (PMS) plan and the PMCF plan under Annex XIV Part B for how the PSUR fits into the broader PMS document set, since the two are related but distinct: PMCF findings feed the PSUR, they are not the same report.

Class IIa versus Class I and Class IIb, at a glance

Requirement	Class I	Class IIa	Class IIb
Conformity assessment	Manufacturer self-declaration (narrow NB exceptions for sterile/measuring/reusable-surgical aspects)	Annex IX (Ch. I & III) or Annex XI Part A + tech-doc assessment	Annex IX (Ch. I & III, representative basis, with design-dossier review for some implantables) or Annex X + XI Part B
Technical documentation review	Not reviewed by a notified body (except narrow exceptions)	Representative basis (by generic device group)	Representative basis, with fuller design-dossier review for certain implantable devices
Clinical evaluation	Literature/equivalence generally sufficient	Literature/equivalence generally sufficient (Art. 61(10))	Often requires more direct clinical data; dedicated investigation more likely
Periodic report	PMS report, updated when necessary (Art. 85)	PSUR, updated when necessary and at least every 2 years, available to NB on request (Art. 86)	PSUR, updated at least annually, actively submitted to NB (Art. 86)

Frequently asked questions

Does every Class IIa device need notified body involvement?

Yes. Unlike most Class I devices, a Class IIa device cannot be self-certified by the manufacturer — it requires a notified body conformity assessment under Annex IX or the Annex XI Part A alternative, resulting in both a QMS certificate and, where applicable, a technical documentation assessment.

Is Class IIa technical documentation reviewed for every device model?

No. Review happens on a representative basis — broadly, at least one representative device per generic device group — rather than a full design-dossier examination of every catalogue variant, which is closer to how Class III is handled.

Does a Class IIa device need a dedicated clinical investigation?

Not automatically. Article 61(10) allows clinical evaluation based on sufficient existing clinical data (literature and equivalent-device data) plus PMCF, provided Annex XIV Part A’s requirements and Article 61(5)’s equivalence criteria are actually met. Class III and implantable devices face a stricter default expectation of a dedicated investigation.

How often is a Class IIa PSUR required?

At least every two years, and whenever otherwise necessary — lighter than the at-least-annual cadence required for Class IIb and Class III, and it only needs to be available to the notified body on request rather than proactively submitted.

Can a Class IIa device be sold in the EU without CE marking?

No. Every Class IIa device needs a valid CE mark, backed by the EU declaration of conformity the manufacturer issues once the applicable Annex IX or Annex XI Part A conformity assessment is complete.

Class IIa Medical Devices Under EU MDR: Conformity Assessment, Notified Body Scope, and PSUR Requirements

Ask about Class IIa Medical Devices Under EU MDR: Conformity Assessment, Notified Body Scope, and PSUR Requirements